Selumetinib increases the efficacy of first-line dacarbazine

Cancer Discov. 2013 Jul;3(7):OF16. doi: 10.1158/2159-8290.CD-RW2013-129. Epub 2013 Jun 13.

Abstract

Selumetinib plus dacarbazine prolongs progression-free survival in BRAF-mutant melanoma.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Benzimidazoles / administration & dosage*
  • Dacarbazine / administration & dosage*
  • Disease-Free Survival
  • Humans
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Melanoma / mortality
  • Mutation
  • Proto-Oncogene Proteins B-raf / genetics
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics
  • Skin Neoplasms / mortality

Substances

  • AZD 6244
  • Benzimidazoles
  • Dacarbazine
  • Proto-Oncogene Proteins B-raf